Validation of the model in a panel of 65 lung cancer cell lines perturbed using PI3K and EGFR/ERBB2 signaling pathway inhibitors revealed general rules of the signaling pathway topology downstream of genetically altered EGFR and ERBB2 kinases. This evidence concerns the gene ERBB2 and lung carcinoma.